Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

3.139.104.122
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Journal Scan
Oncology

COVID-19: Delaying treatment of upper tract urothelial tumors for >3 months worsens outcomes

Posted on

Prioritize the timely care of patients with upper tract urothelial tumors is important as many are delaying treatment due to the COVID-19 pandemic, according to a study that found delaying treatment by >3 months resulted in adverse outcomes in this group of patients.

In this nonsystematic review, manuscripts published until May 23, 2020 that mentioned “uppertract urothelial tumours,” “COVID-19,” and “nephroureterectomy” were reviewed to establish common criteria about the treatment and follow-up needed for these patients.

In total, 4 studies assed the impact of delaying radical nephrouretrectomy as curative treatment, which resulted in decreased overall survival and cancer specific survival rates in high-risk groups. In patients with predominately low-grade disease, delaying radical nephrouretrectomy due to ureteroscopy did not affect survival.

Reference
Galindo Herrero I, Pérez Fentes D, Ríos E, et al. [Current status for urpper tract transitional cell carcinoma during COVID-19 pandemia.]. Arch Esp Urol. 2020;73(5):384-389.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-